公开(公告)号：WO2022241560A1

公开(公告)日：2022-11-24

申请号：PCT/CA2022/050792

申请日：2022-05-19

申请人： QUEEN'S UNIVERSITY AT KINGSTON

发明人： SEAVER, Kyle ,  BASTA, Sam ,  GEE, Katrina

IPC分类号： A61K39/39 ,  A61K31/7088 ,  A61K38/19 ,  A61K38/20 ,  A61K39/00 ,  A61P35/00 ,  A61P37/04 ,  C07K14/52 ,  C07K14/705 ,  C12N15/115 ,  C12N15/117

摘要： A cancer vaccine includes at least one tumour associated antigen (TAA), at least one Toll-like receptor (TLR) agonist, at least one cytokine, and a pharmaceutically acceptable vehicle. The at least one TAA may be provided by dead tumour cells, such as γ-irradiated tumour cells or lysis and UV treated tumour cells, the at least one TLR agonist may comprise 5 CpG-1826 and the at least one cytokine may comprise IL-27. When administered to a mammalian subject the cancer vaccine prevents, inhibits, or slows tumour development in the subject, and the vaccine may provide a long-term T cell activation and memory against tumour development in the subject. 0